Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in the pathogenesis of systemic sclerosis.

Lazaros I Sakkas1

  • 1Thessaly University School of Medicine, Larisa 412-22, Greece. lsakkas@med.uth.gr

Autoimmunity
|July 26, 2005
PubMed
Summary

Systemic sclerosis involves fibrosis and immune system activation. Targeting immune cells and cytokines shows promise for treating this complex fibrotic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.

Rheumatology and therapy·2026
Same author

Apremilast therapy increases CD39<sup>+</sup>CD4<sup>+</sup> T cells in peripheral blood of patients with psoriatic disease: a retrospective observational pilot study.

Rheumatology international·2026
Same author

Cell immunotherapy in autoimmune rheumatic diseases: a paradigm shift in the therapy of autoimmune inflammatory rheumatic diseases.

Clinical rheumatology·2026
Same author

Chimeric antigen receptor macrophage (CAR-M) immunotherapy in autoimmune inflammatory rheumatic diseases.

Clinical rheumatology·2026
Same author

Potential of CAR-T cell immunotherapy in rheumatoid arthritis.

Clinical rheumatology·2026
Same author

Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE).

Clinical rheumatology·2026

Area of Science:

  • Immunology
  • Pathophysiology
  • Rheumatology

Background:

  • Systemic sclerosis (SSc) is a fibrotic disease characterized by vascular damage and immune system dysregulation.
  • Key profibrotic factors include transforming growth factor-beta (TGF-β), interleukin-4 (IL-4), and platelet-derived growth factor (PDGF).
  • Immune cell activation, particularly T cells and B cells, plays a critical role in SSc pathogenesis.

Purpose of the Study:

  • To review the role of immune system activation in systemic sclerosis.
  • To highlight the impact of immune cells and cytokines on fibrosis and vasculopathy in SSc.
  • To discuss the therapeutic implications of targeting immune pathways in SSc.

Main Methods:

  • Literature review of recent studies on SSc pathogenesis.
  • Analysis of the roles of cytokines and immune cells (T cells, B cells) in SSc.
  • Examination of therapeutic strategies targeting immune mediators.

Main Results:

  • T cells infiltrate SSc lesions, producing the profibrotic cytokine IL-4 and driving autoantibody production.
  • B cells may contribute to fibrosis, as evidenced by reduced fibrosis in CD19-deficient models.
  • Anti-endothelial cell autoantibodies are implicated in vasculopathy and vessel paucity in SSc.

Conclusions:

  • Immune system activation is central to the pathogenesis of systemic sclerosis.
  • Emerging therapies targeting immune cells and soluble factors demonstrate encouraging preliminary results in SSc treatment.

Related Experiment Videos